Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$0.56
$0.65
$0.51
▼
$1.83
$22.79M-0.3939,674 shs11,356 shs
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$2.00
$1.96
$1.22
▼
$7.92
$30M1.1138,230 shs9,703 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%-7.34%-10.05%-14.28%-60.58%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
0.00%-3.38%+5.26%+10.07%+199,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$0.56
$0.65
$0.51
▼
$1.83
$22.79M-0.3939,674 shs11,356 shs
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$2.00
$1.96
$1.22
▼
$7.92
$30M1.1138,230 shs9,703 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%-7.34%-10.05%-14.28%-60.58%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
0.00%-3.38%+5.26%+10.07%+199,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
2.00
Hold$4.00617.10% Upside
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
3.00
Buy$8.00300.00% Upside

Current Analyst Ratings Breakdown

Latest GWP, BRNS, SER, and GKO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/1/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
7/1/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
6/15/2026
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/28/2026
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/8/2026
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M1.52N/AN/A$1.82 per share0.31
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$130K230.77N/AN/A($0.46) per share-4.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%8/6/2026 (Estimated)
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
-$19.18MN/AN/AN/AN/AN/A-8,051.54%-155.08%N/A

Latest GWP, BRNS, SER, and GKO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.28N/AN/AN/AN/AN/A
5/14/2026Q1 2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
N/A-$0.58N/A-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
6.05
6.05
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
0.24
4.18
4.18

Institutional Ownership

CompanyInstitutional Ownership
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
12.50%

Insider Ownership

CompanyInsider Ownership
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
8.50%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
17.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.85 million37.38 millionN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
N/A15.00 million12.34 millionN/A

Recent News About These Companies

Serina Therapeutics, Inc.: Serina Therapeutics Appoints Farrell Simon to its Board of Directors
July 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69102432-serina-therapeutics-inc-serina-therapeutics-appoints-farrell-simon-to-its-board-of-directors-399.htm
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332737/0/en/serina-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference.html
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
July 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/serina-therapeutics-announces-completion-of-enrollment-and-dosing-in-cohort-1-of-registrational-trial-of-ser-252-for-advanced-parkinson-s-disease-1036356239
Serina Therapeutics Amends CEO Employment and Compensation Terms
July 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/serina-therapeutics-amends-ceo-employment-and-compensation-terms?utm_source=marketbeat.com&utm_medium=referral
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331950/0/en/serina-therapeutics-announces-completion-of-enrollment-and-dosing-in-cohort-1-of-registrational-trial-of-ser-252-for-advanced-parkinson-s-disease.html
Serina Therapeutics Adds Industry Veteran to Board
July 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/serina-therapeutics-adds-industry-veteran-to-board?utm_source=marketbeat.com&utm_medium=referral
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331754/0/en/serina-therapeutics-appoints-farrell-simon-to-its-board-of-directors.html
Serina concludes sentinel dosing in Phase Ib trial’s cohort 1
July 13, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/serina-concludes-sentinel-dosing-in-phase-ib-trial-s-cohort-1/ar-AA27PHs0
Serina Therapeutics Inc SER
July 11, 2026  |  morningstar.comM
Serina Therapeutics, Inc.: Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
July 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68993601-serina-therapeutics-inc-serina-therapeutics-announces-completion-of-sentinel-dosing-in-cohort-1-of-phase-1b-registrational-trial-of-ser-252-for-adv-399.htm
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
July 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/serina-therapeutics-announces-completion-of-sentinel-dosing-in-cohort-1-of-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinson-s-disease-1036311719
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
July 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/09/3325085/0/en/serina-therapeutics-announces-completion-of-sentinel-dosing-in-cohort-1-of-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinson-s-disease.html
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319771/0/en/gannet-biochem-and-serina-therapeutics-enter-development-partnership-supporting-ser-252-program.html
Serina Therapeutics Shareholders Approve Expanded Equity and Governance
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/serina-therapeutics-shareholders-approve-expanded-equity-and-governance?utm_source=marketbeat.com&utm_medium=referral
Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $17,700.00 in Stock
May 27, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyseamerican-ser-insider-buying-and-selling-2026-05-27/
Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in Stock
May 23, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyseamerican-ser-insider-buying-and-selling-2026-05-23/
Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks
May 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/insider-backed-pipe-deal-may-dilute-serina-therapeutics-shareholders-and-heighten-governance-risks?utm_source=marketbeat.com&utm_medium=referral
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295408/0/en/serina-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates.html
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3268918/0/en/serina-therapeutics-to-present-at-the-5th-lnp-formulation-process-development-summit.html
Serina Therapeutics: Clinical Progress Overshadowed by Financial Strain
April 3, 2026  |  aktiencheck.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A red downward-pointing zigzag arrow emerges from a tablet screen displaying a falling stock chart, symbolizing market declines and negative financial momentum.
Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
By Thomas Hughes | July 6, 2026
Amazon logo at the center of a glowing digital sphere with data streams in a server room.
Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
By Jeffrey Neal Johnson | July 10, 2026
Illustrated stablecoin tokens including Tether (USDT), USD Coin (USDC), Dai, and TrueUSD scattered across a dark background.
Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
By Jeffrey Neal Johnson | July 5, 2026
Supermicro logo displayed over a data center aisle lined with server racks and networking equipment.
Pushing the Edge: Super Micro Computer Reboots the AI Landscape
By Jeffrey Neal Johnson | July 11, 2026
Semiconductor lithography equipment processes a silicon wafer with a chip pattern under a purple light source.
Apple and Broadcom Forge a Decade-Long Silicon Fortress
By Jeffrey Neal Johnson | July 7, 2026
Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$0.56 +0.01 (+1.29%)
As of 07/31/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Serina Therapeutics stock logo

Serina Therapeutics NYSEAMERICAN:SER

$2.00 0.00 (0.00%)
Closing price 07/31/2026 04:10 PM Eastern
Extended Trading
$2.01 +0.01 (+0.50%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas